Recent News & Research

*January 2020* Oncoprex in combination with osimertinib (Tagrisso) received fast track designation from the FDA to treat patients with non-small cell lung cancer (NSCLC) with EFGR mutations that progressed after treatment with osimertinib alone, according to Genprex, Inc., the immunogene therapy’s manufacturer. Read more.

*January 2020* The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application (sBLA) for intravenous ramucirumab (Cyramza) injection for use in combination with erlotinib (Tarceva) in the frontline treatment of patients with metastatic non–small cell lung…

*January 2020* Dana-Farber’s Pasi Jänne, MD, PhD, and his colleagues say they have discovered a mechanism within lung cancer cells that enables the cells to lie dormant and avoid destruction by the cancer drugs. Read more.

*December 2019* With the inevitability of resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non–small cell lung cancer (NSCLC), novel options like lazertinib (YH25448), an irreversible, third-generation, mutant-selective, EGFR TKI are being explored. Lazertinib has shown promise for the treatment of this patient population, according…

*December 2019* SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company filed an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and the Ministry of Food and Drug Safety (MFDS) in Korea to initiate…

*December 2019* Adding chemotherapy to a targeted agent doubled progression-free survival (PFS) for patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), according to two randomized trials. A phase III trial from India showed that median PFS increased from 8 months with the EGFR inhibitor gefitinib (Iressa) to 16 months with gefitinib…

*December 2019* Patients with EGFR-mutant (m) non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LM) respond favorably to high daily doses of osimertinib, phase 1 BLOOM study data suggest. Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Seoul, Republic of Korea) and study co-authors say that “osimertinib has the potential to become a…